Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,571
Out of 4,583 analysts
13
Total ratings
10%
Success rate
-60.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.56 | +212.50% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $6.73 | +1,385.88% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.68 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $5.93 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $1.08 | +13,788.89% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.30 | +354.55% | 1 | Jun 29, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $3.94 | +2,184.26% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.77 | +3,925.97% | 2 | May 18, 2022 | |
| DRMA Dermata Therapeutics | Initiates: Buy | $3,360 | $2.25 | +149,233.33% | 1 | Sep 21, 2021 | |
| ONCT Oncternal Therapeutics | Initiates: Buy | $320 | $1.65 | +19,293.94% | 1 | Mar 30, 2021 |
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.56
Upside: +212.50%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $6.73
Upside: +1,385.88%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.68
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.93
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $1.08
Upside: +13,788.89%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.30
Upside: +354.55%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $3.94
Upside: +2,184.26%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.77
Upside: +3,925.97%
Dermata Therapeutics
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $2.25
Upside: +149,233.33%
Oncternal Therapeutics
Mar 30, 2021
Initiates: Buy
Price Target: $320
Current: $1.65
Upside: +19,293.94%